BrightSpring Health Services, Inc. Reports Third Quarter 2026 Financial Results and Increases Full Year 2026 Guidance

BrightSpring posts strong Q3 growth and raises full-year 2026 guidance across all metrics.

What the company is saying

BrightSpring Health Services, Inc. (NASDAQ: BTSG) is highlighting a robust third quarter, with net revenue of $4,213 million, a 26.4% increase over Q3 2025, and gross profit of $519 million, up 32.3%. The company frames these results as evidence of effective operational execution and a clear value proposition for healthcare stakeholders. Jon Rousseau, Chairman, President, and CEO, attributes the performance to team commitment and process improvements, expressing high confidence in future growth. The company is also emphasizing improved profitability, with net income from continuing operations rising to $101 million from $38 million and Adjusted EBITDA up 42% to $228 million. Leverage has decreased to 1.79x from 2.15x in the prior quarter, signaling balance sheet improvement. BrightSpring is raising its full-year 2026 guidance, projecting revenue between $15,900 million and $16,125 million and Adjusted EBITDA between $850 million and $860 million, with the Amedisys and LHC acquisition expected to add $35 million in Adjusted EBITDA. The tone is confident, focusing on both realised results and near-term growth expectations.

What the data suggests

The disclosed figures show strong year-over-year growth in every major financial metric. Net revenue for Q3 2026 rose to $4,213 million from $3,334 million, and gross profit increased to $519 million from $392 million. Net income from continuing operations nearly tripled to $101 million from $38 million, while Adjusted EBITDA climbed 42% to $228 million. Segment data show Pharmacy Solutions revenue at $3,732 million and Provider Services at $481 million, both up significantly. For the first nine months of 2026, total revenue reached $11,700 million, up from $9,360 million. Operational metrics reinforce this trend: prescriptions dispensed rose 2% to 10,949,875, revenue per script increased 24% to $340.86, and gross profit per script rose 27% to $28.86. Home Health Care average daily census jumped 58% to 47,256. The company’s leverage ratio improved to 1.79x from 2.15x in the previous quarter. Full-year guidance implies continued double-digit growth, with revenue expected to rise 23.2–24.9% and Adjusted EBITDA 37.6–39.3%. The Amedisys and LHC acquisition is projected to contribute $35 million in Adjusted EBITDA in 2026. The data quality is high, with segment and consolidated results, operational metrics, and clear separation of realised versus guided figures.

Analysis

The announcement is strongly positive and proportionate to the disclosed results. The company provides detailed, realised financial data for Q3 and the first nine months of 2026, including net revenue, gross profit, net income, and adjusted EBITDA, all showing substantial year-over-year growth. Profitability metrics are disclosed alongside revenue, satisfying the completeness rule for a strong_positive signal. Forward-looking statements (full-year guidance and expected acquisition contribution) are clearly separated from realised results and are near-term (for the current fiscal year). There is no evidence of narrative inflation or exaggerated claims; the CEO's commentary is supportive but not excessive. The only capital-intensive item (Amedisys and LHC acquisition) is expected to contribute to EBITDA within the current year, so the capital intensity flag is not triggered. The data fully supports the positive tone.

Risk flags

• ●Integration risk from the Amedisys and LHC branches acquisition could impact the expected $35 million Adjusted EBITDA contribution if operational or cultural challenges arise, as integration of acquired assets is often complex in healthcare services.
• ●Sustaining high growth rates in both revenue and profitability may become more difficult as the company scales, especially given the 26–32% year-over-year increases already achieved; any slowdown could pressure valuation multiples.
• ●Leverage has improved to 1.79x, but further acquisitions or unexpected operational setbacks could reverse this trend, especially if integration costs or working capital needs are underestimated.
• ●Guidance assumes no material adverse changes in reimbursement rates, regulatory environment, or payer mix; shifts in Medicare or Medicaid policy could quickly affect margins and revenue projections.
• ●The company’s results exclude the divested Community Living business, so comparability with prior periods relies on consistent segment definitions; any future portfolio changes could complicate trend analysis.

Bottom line

BrightSpring’s Q3 2026 results show accelerating growth in revenue, profit, and cash generation, with all major financial and operational metrics improving year-over-year. The company’s raised full-year guidance and improved leverage ratio indicate strong near-term momentum and disciplined balance sheet management. The expected $35 million EBITDA contribution from the Amedisys and LHC acquisition is additive but not transformative, and successful integration will be key to realising this benefit. While the current trajectory is positive, investors should watch for any signs of integration challenges, reimbursement headwinds, or slowing growth as the company scales. The most important takeaway is that BrightSpring is executing well on its core business and delivering on its guidance, but continued outperformance will depend on maintaining operational discipline and successfully integrating new assets.

Announcement summary

(NASDAQ: BTSG) BrightSpring Health Services, Inc. announced financial results for the third quarter ended September 30, 2026, and increased its full year 2026 Revenue and Adjusted EBITDA guidance. The company reported net revenue of $4,213 million for Q3 2026, a 26.4% increase from $3,334 million in Q3 2025. Gross profit for the quarter was $519 million, up 32.3% from $392 million in the prior year period. Net income from continuing operations was $101 million, compared to $38 million in Q3 2025. Adjusted EBITDA for the quarter was $228 million, a 42.0% increase from $160 million in Q3 2025. Leverage as of September 30, 2026, was 1.79x, compared to 2.15x on June 30, 2026. Pharmacy Solutions Revenue for Q3 2026 was $3,732 million, up from $2,967 million in Q3 2025, and Provider Services Revenue was $481 million, up from $367 million. For the nine months ended September 30, 2026, total revenue was $11,700 million, compared to $9,360 million for the same period in 2025. Pharmacy Solutions Segment EBITDA for Q3 2026 was $202 million, up from $141 million, and Provider Services Segment EBITDA was $79 million, up from $61 million. Total Segment EBITDA for Q3 2026 was $281 million, compared to $202 million in Q3 2025. Corporate costs for Q3 2026 were $(53) million, compared to $(41) million in Q3 2025. Total Company Adjusted EBITDA for the nine months ended September 30, 2026, was $623 million, compared to $434 million in the prior year period. Pharmacy Solutions dispensed 10,949,875 prescriptions in Q3 2026, up 2% from 10,793,219 in Q3 2025, with revenue per script of $340.86 and gross profit per script of $28.86. Provider Services Home Health Care average daily census was 47,256 in Q3 2026, up 58% from 29,980 in Q3 2025. Rehab Care persons served was 7,574, up 9% from 6,932, and Personal Care persons served was 16,320, up 1% from 16,134. Effective July 1, 2026, the company realigned its Rehab in Motion business from the Rehab Care sub-segment to the Home Health Care sub-segment. For full year 2026, BrightSpring increased its guidance to revenues of $15,900 million to $16,125 million, representing 23.2% to 24.9% growth over 2025. Pharmacy Segment Revenue is guided to $14,000 million to $14,200 million, or 22.3% to 24.1% growth, and Provider Segment Revenue to $1,900 million to $1,925 million, or 29.7% to 31.4% growth. Total Adjusted EBITDA is guided to $850 million to $860 million, or 37.6% to 39.3% growth. The Amedisys and LHC branches acquisition is expected to contribute approximately $35 million in Adjusted EBITDA in 2026. Jon Rousseau, Chairman, President, and Chief Executive Officer, stated that the results reflect the team's commitment to patient care and operational execution, and expressed confidence in the company's future growth. The company will host a conference call on October 30 at 8:30 a.m. Eastern Time, with supplemental information available on its investor relations website.

Disagree with this article?